Exosome Scalp Therapy vs PRP for Hair: What the Evidence Shows (and Doesn't)

The honest framing: both are adjuncts, neither is approved to address hair loss

When comparing exosome vs PRP hair protocols, the first fact that deserves clarity is regulatory status. Platelet-rich plasma and exosome-based scalp injections are not FDA approved to treat any disease, including androgenetic alopecia. Both are used off-label in clinical practice, and the quality of the evidence supporting each differs substantially. Platelet-rich plasma draws from the patient's own blood; devices that prepare PRP are cleared for that preparation step, but the application to hair loss itself remains investigational. Exosome products marketed for scalp injection are typically derived from donor mesenchymal stromal cell cultures and are not approved by the FDA for any indication. The FDA issued a public safety notification in December 2019 after serious adverse events were reported in patients who received unapproved exosome products, and a consumer alert on regenerative medicine marketing followed. Springs Rejuvenation offers the Stem Cell Exosome Scalp Protocol as an investigational adjunct — not as a standalone solution and not as a substitute for diagnosis. Individual responses vary, and the purpose of this page is to present what the published literature shows, what it does not show, and how Dr. Charles Pereyra, MD, frames these options during a consultation.

What PRP is and what the trials show — including the null ones

Platelet-rich plasma is autologous plasma that has been centrifuged to concentrate platelets and their associated growth factors. The hypothesis is that injecting this concentrate into the scalp may signal dermal papilla cells to prolong anagen phase and support vascularization. Gentile and colleagues (2015) conducted a randomized placebo-controlled half-head study in men with androgenetic alopecia and reported increased hair density on the PRP-injected side at follow-up. Zhang and colleagues (2023) performed a systematic review and meta-analysis of randomized trials and found improved hair density with PRP versus control, though they noted substantial heterogeneity in preparation methods and session frequency. Giordano and colleagues (2017) pooled small trials in a meta-analysis and similarly reported increased hair density with PRP, again with wide variation between protocols.

However, not every randomized trial has found a benefit. Mapar and colleagues (2016) conducted a small pilot trial in men that did not find a significant improvement with PRP. Puig and colleagues (2016) ran a double-blind placebo-controlled pilot in women with female pattern hair loss and did not show a significant objective difference versus placebo. De Oliveira and colleagues (2023) reviewed the evidence specifically in women and described it as limited and heterogeneous. The variation in outcomes may reflect differences in platelet concentration, activation method, number of sessions, or patient selection, but it underscores that PRP for hair loss is not a uniform intervention and that publication bias may favor positive studies. PRP protocols differ in spin speed, anticoagulant, whether platelets are activated before injection, and whether sessions are monthly or quarterly, and pooled estimates must be interpreted cautiously.

What exosomes are and how thin the human evidence still is

Exosomes are nanometer-scale extracellular vesicles that carry proteins, lipids, and RNA between cells. The exosome products marketed for scalp injection are typically derived from cultures of donor mesenchymal stromal cells and are not prepared from the patient. The hypothesis, drawn largely from cell-culture and animal models, is that these vesicles may deliver signaling cargo to follicular cells and influence the hair cycle. Malih and colleagues (2026) conducted a systematic review of preclinical exosome studies in androgenetic alopecia — the evidence base was in vitro and in animal models, not human trials. Kost and colleagues (2022) reviewed the literature on exosomes in hair regeneration and found that the majority of the evidence was preclinical, with very few human studies. Gupta and colleagues (2023) performed a systematic review of exosome use in hair restoration and reported that the preliminary human evidence came from small, non-standardized studies with variable product characterization, dosing, and limited safety data. Shin and colleagues (2017) reviewed small clinical trials of adipose-derived stem cell conditioned media, which contains exosomes among other factors, in pattern hair loss; the studies were early-phase and heterogeneous.

The absence of large, placebo-controlled human trials and the lack of standardized exosome characterization mean that claims about efficacy or safety in humans rest on a much thinner foundation than those for PRP. When evaluating exosome vs PRP hair evidence, the difference in the maturity of the literature is stark.

Regulatory status: the FDA's 2019 safety notification and consumer alert

In December 2019, the FDA issued a public safety notification stating that there are no FDA-approved exosome products and that the agency had received reports of serious adverse events in patients in Nebraska who received unapproved exosome products. The FDA has also published a consumer alert on regenerative medicine products, including stem cells and exosomes, warning that such products are not approved for any use other than within approved clinical trials and cautioning about clinics that market them without proper oversight. These notifications apply to exosome scalp injections: the products are not FDA approved to treat any disease, including hair loss.

PRP preparation devices have FDA clearance for preparing platelet-rich plasma, but PRP for hair loss is an off-label application; no PRP product is FDA approved for hair loss. Both interventions are used in practice based on investigational rationale and the preliminary evidence described above, not on regulatory approval.

Exosome vs PRP hair side by side

What the evidence does not show yet — for either

Neither the PRP literature nor the exosome literature answers several questions that matter in practice. Durability beyond twelve months is rarely reported in randomized trials. Head-to-head comparisons of exosome vs PRP hair protocols are absent, so any claim that one outperforms the other is unsupported. Optimal dosing, session frequency, and interval between sessions remain undefined; the variation between published protocols is wide. Predictors of response — which patients are most likely to see a density increase and which are least likely — have not been characterized. For exosomes specifically, product characterization is inconsistent; vesicle size distribution, cargo profiling, and potency assays are not standardized across manufacturers, making it difficult to know whether results from one product generalize to another. For PRP, activation method (calcium chloride, freeze-thaw, or none) and platelet concentration vary, and it is not clear which parameters matter most. In short, the exosome vs PRP hair question cannot yet be answered with confidence because both remain early in the evidence-development process and both have significant gaps.

Where regenerative adjuncts can fit: medication first, FUE when indicated

The interventions with the strongest trial base in androgenetic alopecia are finasteride and topical minoxidil. Kaufman and colleagues (1998) conducted two-year randomized placebo-controlled trials of finasteride one milligram daily in over fifteen hundred men aged eighteen to forty-one and showed increased hair counts versus placebo, with progression in the placebo group. Olsen and colleagues (2002) ran a randomized trial in men comparing five percent topical minoxidil to two percent and placebo, and the five percent preparation outperformed both on hair count at forty-eight weeks. Lucky and colleagues (2004) conducted a randomized placebo-controlled trial of five percent and two percent topical minoxidil in women with female pattern hair loss, and both concentrations beat placebo on hair count at forty-eight weeks. Low-dose oral minoxidil is used off-label; Vañó-Galván and colleagues (2021) reported on a multicenter series of over fourteen hundred patients, finding that hypertrichosis was the most common adverse effect and that discontinuation for side effects was uncommon.

When medication alone does not meet a patient's goals, follicular unit excision offers a surgical option. The ISHRS 2025 Practice Census, which surveys member activity, reported that FUE harvesting was used in over eighty-five percent of male surgical procedures and that the average FUE case involved over two thousand grafts. The census found that men represented about eighty-five percent of surgical patients and that the most common patient-stated reasons for surgery were to become or feel more attractive and to appear younger to compete in the workplace. Dr. Charles Pereyra, MD, personally performs the Micrograft FUE procedure — extraction and placement are not delegated to a physician assistant or technician — and Springs Rejuvenation has performed over seven thousand procedures.

Balwi and colleagues (2026) reviewed adjunctive regenerative therapies around hair transplantation, including PRP and exosomes, and described the evidence base as early and heterogeneous. The role of these adjuncts, if any, is to support medication or to be considered around the time of FUE, never to replace a physician-led diagnosis or the interventions with established trial data. Individual responses vary, and candidacy depends on pattern, donor density, medical history, and patient goals.

How Springs approaches the Stem Cell Exosome Scalp Protocol

Springs Rejuvenation offers the Stem Cell Exosome Scalp Protocol as an investigational adjunct. It is not FDA approved to treat any disease. Dr. Charles Pereyra, MD, a board-certified emergency physician and member of the International Society of Hair Restoration Surgery, conducts the initial physician evaluation. He reviews medical history, examines the scalp, discusses pattern and progression, and frames realistic expectations. Some requests are declined — for instance, when a patient has not tried or cannot tolerate the medications with the strongest trial evidence, or when expectations do not align with what the investigational literature supports. Consent includes a discussion of regulatory status, the preliminary nature of the human evidence, the absence of long-term safety data, and the fact that individual responses vary.

Springs provides one all-in price quoted at the consultation, not a per-session or per-vial estimate, and that quote covers the physician evaluation, the protocol itself, and follow-up. The practice operates five clinics: Aventura, Florida; Los Angeles, California; Austin, Texas; Atlanta, Georgia; and New York, New York. Phone for every location is 888-503-4482. For out-of-state patients, Springs offers a travel program: virtual consultation, written care plan, travel to the clinic, the procedure, an in-person recovery check before flying home, and remote follow-up. The exosome vs PRP hair discussion happens during the consultation, not before it, because the decision depends on the individual findings and the physician's clinical judgment.

Frequently asked questions

Is PRP FDA approved for hair loss?

No. PRP preparation devices have FDA clearance for preparing platelet-rich plasma, but PRP for hair loss is an off-label use and no PRP product is FDA approved for hair loss. The evidence supporting its use comes from investigational trials, some positive and some null, with wide variation in protocols. Individual responses vary, and PRP is discussed as an adjunct during a physician evaluation, not as a standalone approved therapy.

Are exosome scalp therapies FDA approved?

No. The FDA has stated that there are no FDA-approved exosome products. Exosome scalp injections are not FDA approved to treat any disease, including hair loss. The FDA issued a public safety notification in December 2019 after serious adverse events were reported in patients who received unapproved exosome products, and a consumer alert warns about clinics marketing regenerative medicine products without proper oversight. The human evidence for exosomes in hair restoration is preliminary, coming from small, non-standardized studies with limited safety data.

Which has more evidence, exosome vs PRP hair protocols?

PRP has more human evidence. There are randomized placebo-controlled trials of PRP in androgenetic alopecia, some showing increased hair density and some showing no significant benefit, and there are meta-analyses pooling these trials. Exosome evidence is mostly preclinical, from cell culture and animal models, with very few human studies and no large randomized trials. The exosome vs PRP hair comparison is not close when evaluated on the basis of published human data.

Can either replace finasteride or minoxidil?

No. Finasteride and topical minoxidil have the strongest trial base in androgenetic alopecia, with large randomized placebo-controlled studies showing efficacy. Neither PRP nor exosomes have evidence approaching that standard, and both are used investigationally as adjuncts, not replacements. A physician-led evaluation begins with a discussion of the medications with established trial data, and regenerative protocols are considered only after that conversation, if candidacy and patient goals align.

Can exosome or PRP protocols be combined with FUE?

Some practitioners use PRP or exosome injections around the time of follicular unit excision, based on the hypothesis that growth factors or signaling vesicles may support graft survival or tissue recovery. However, the evidence that adding these adjuncts improves FUE outcomes is limited and heterogeneous. Springs Rejuvenation discusses adjunctive options during the consultation with Dr. Pereyra, and any decision to combine protocols depends on the individual case, the physician's clinical judgment, and the patient's informed consent. Individual responses vary.

About the author: Dr. Charles Pereyra, MD, is a board-certified emergency physician (NewYork-Presbyterian Brooklyn Methodist), a member of the International Society of Hair Restoration Surgery (ISHRS), and the physician who personally performs Micrograft FUE procedures at Springs Rejuvenation Hair.

Medical disclaimer: Stem cell and exosome therapy is not an FDA approved therapy and is considered to be in the experimental stages; it is not FDA approved to treat any disease. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Reviewed for medical accuracy by Dr. Charles Pereyra, MD, Medical Director, Springs Rejuvenation.